Nova Eye Medical Future Growth
Future criteria checks 6/6
Nova Eye Medical is forecast to grow earnings and revenue by 102.3% and 26.3% per annum respectively. EPS is expected to grow by 101.6% per annum. Return on equity is forecast to be 25.3% in 3 years.
Key information
102.3%
Earnings growth rate
101.6%
EPS growth rate
| Medical Equipment earnings growth | 16.0% |
| Revenue growth rate | 26.3% |
| Future return on equity | 25.3% |
| Analyst coverage | Low |
| Last updated | 01 Sep 2024 |
Recent future growth updates
Recent updates
Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%
Sep 22
Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)
Aug 06Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward
Apr 18Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?
Mar 26News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts
Jan 19Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce
Dec 27We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate
Sep 03Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified
Apr 17Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?
Dec 16We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Aug 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 53 | 6 | 5 | 7 | 2 |
| 6/30/2026 | 42 | 1 | 0 | 2 | 2 |
| 6/30/2025 | 32 | -3 | -3 | -1 | 2 |
| 6/30/2024 | 23 | -9 | -8 | -8 | N/A |
| 3/31/2024 | 21 | -12 | -8 | -7 | N/A |
| 12/31/2023 | 19 | -14 | -7 | -6 | N/A |
| 9/30/2023 | 18 | -15 | -7 | -7 | N/A |
| 6/30/2023 | 17 | -15 | -8 | -7 | N/A |
| 3/31/2023 | 16 | -13 | -9 | -8 | N/A |
| 12/31/2022 | 15 | -11 | -10 | -9 | N/A |
| 9/30/2022 | 14 | -9 | -10 | -7 | N/A |
| 6/30/2022 | 13 | -7 | -10 | -5 | N/A |
| 3/31/2022 | 13 | -7 | -13 | -8 | N/A |
| 12/31/2021 | 13 | -6 | -16 | -11 | N/A |
| 9/30/2021 | 13 | -5 | -16 | -12 | N/A |
| 6/30/2021 | 13 | -4 | -15 | -13 | N/A |
| 12/31/2020 | 12 | -9 | -1 | 0 | N/A |
| 9/30/2020 | 13 | -10 | 2 | 3 | N/A |
| 6/30/2020 | 13 | -10 | 4 | 5 | N/A |
| 12/31/2019 | 16 | -6 | -4 | -1 | N/A |
| 9/30/2019 | 16 | -6 | -6 | -2 | N/A |
| 6/30/2019 | 16 | -7 | -8 | -4 | N/A |
| 3/31/2019 | 48 | -7 | -7 | -2 | N/A |
| 12/31/2018 | 49 | -6 | -6 | -1 | N/A |
| 9/30/2018 | 64 | -6 | -6 | 0 | N/A |
| 6/30/2018 | 79 | -5 | -6 | 1 | N/A |
| 3/31/2018 | 77 | -5 | N/A | -2 | N/A |
| 12/31/2017 | 75 | -5 | N/A | -4 | N/A |
| 9/30/2017 | 73 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 72 | -1 | N/A | -3 | N/A |
| 3/31/2017 | 72 | 1 | N/A | -1 | N/A |
| 12/31/2016 | 73 | 3 | N/A | 2 | N/A |
| 9/30/2016 | 73 | 3 | N/A | 3 | N/A |
| 6/30/2016 | 73 | 3 | N/A | 5 | N/A |
| 3/31/2016 | 70 | 3 | N/A | 6 | N/A |
| 12/31/2015 | 67 | 2 | N/A | 7 | N/A |
| 9/30/2015 | 65 | 2 | N/A | 7 | N/A |
| 6/30/2015 | 63 | 2 | N/A | 7 | N/A |
| 3/31/2015 | 61 | 1 | N/A | 5 | N/A |
| 12/31/2014 | 59 | 1 | N/A | 4 | N/A |
| 9/30/2014 | 57 | 1 | N/A | 3 | N/A |
| 6/30/2014 | 54 | 1 | N/A | 3 | N/A |
| 3/31/2014 | 51 | 0 | N/A | 2 | N/A |
| 12/31/2013 | 47 | -1 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EYE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: EYE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EYE is expected to become profitable in the next 3 years.
Revenue vs Market: EYE's revenue (26.3% per year) is forecast to grow faster than the Australian market (5.6% per year).
High Growth Revenue: EYE's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EYE's Return on Equity is forecast to be high in 3 years time (25.3%)